Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning

Contributed by: Business Wire

Images

Ricimed - Fabentech
Ricimed - Fabentech
Business Wire embedded0

Tags

Health
Defense
Infectious Diseases
Military
Pharmaceutical
Biotechnology
Ricimed

More Like This

PR Newswire associated0

Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership

PR Newswire associated0

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships

Business Wire logo

Samabriva is Set to Become a World Leader in Precision Biomanufacturing of Complex Molecules With the Announcement of a €4 Million Fundraising Round

MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology